Patient registry for AQP4+ neuromyelitis optica on C5 inhibitors
Part of Brain & nervous system, Eyes & vision, Immune system & allergy clinical trials.
This registry collects health and relapse information from adults with AQP4-positive NMOSD who are taking C5-blocking medicines to prevent long-term relapses. It helps researchers better understand treatment patterns and outcomes in real-world care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older
- Have a confirmed diagnosis of AQP4+ NMOSD
- Be currently taking a C5 inhibitor called ALXN-C5IT for preventing chronic relapses
- Have had eculizumab within the last 4 weeks or ravulizumab within the last 12 weeks
- Have records of your ALXN-C5IT dosing since you started and your relapses from 1 year before starting through now
- Not be in a current drug interventional trial for AQP4+ NMOSD
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new treatment called CC-97540 (a type of CAR T-cell therapy) for people with neuromyelitis optica spectrum disorder (NMOSD), which is an autoimmune disease that affects the eyes and spinal cord. The goal is to see if this treatment is safe and tolerable.
This is a registry that collects health information from adults with neuromyelitis optica spectrum disorder (NMOSD). It aims to better understand NMOSD and support future research, including studies of emerging therapies.
This trial compares several medications to see which works best for NMOSD, an autoimmune disease that can cause vision loss and paralysis. You must have a specific antibody (AQP4-IgG) to join.
This trial tests a new antibody-based medicine to help people recover from an acute attack of neuromyelitis optica spectrum disorder (NMOSD), a condition that causes inflammation in the eyes and spinal cord. If you are having a recent flare-up and are already getting or planning to get steroid treatment, this study might offer an additional option to reduce damage and speed recovery.
This trial studies ofatumumab to reduce disease activity in adults with AQP4-IgG positive NMOSD who have had recent relapses. It may help lower the chance of new attacks and help prevent worsening disability over time.
This study follows people with NMOSD (a rare autoimmune disease affecting the brain and spinal cord) to learn more about the condition and how it affects patients over time. It involves regular check-ups and MRI scans, with the goal of improving future care and treatment.
Hear when a new Neuromyelitis Optica Spectrum Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.